Tributyrin is butter fat repurposed as a delivery device, carrying butyric acid past the stomach to fuel the cells lining the colon, where imaging confirms it arrives. No controlled trial of tributyrin alone has reported a health outcome; supportive evidence rests on a related salt form, animals and cell culture. Digestive upset and rancid-butter odour rise with dose. (Full Review)

Protocol

Standard supplement dose

300–600 mg once or twice daily

Range in commercial products, typically 150–300 mg of butyrate equivalents per capsule

Research-grade dose

500 mg orally three times daily

Best-characterised human regimen, with imaging confirmation

Best time of day

With meals, in split doses

Tied to meals rather than the clock, since hydrolysis depends on lipase and bile; where sleep is a target, the evening dose is taken with the last meal

Time to effect

Stool inflammation markers

8–12 weeks

Gut barrier integrity and colonic inflammation; measured with the salt form, so indirect

Weight measures

6 months

Body weight and insulin resistance markers; measured with the salt form in children, so indirect

Imaging and inflammatory markers

30 days

Cognitive and motor function in Parkinson's disease, from an uncontrolled study

Benefits

Low: Gut barrier integrity and colonic inflammation; cognitive and motor function in Parkinson's disease; body weight and insulin resistance markers; self-reported anxiety and digestive quality of life; tumour growth control in advanced solid tumours (conflicted)

Speculative: Visceral adipose tissue inflammation; hepatic fat and alcohol-related liver injury; skeletal muscle regenerative capacity; vascular wall protection; microbial shift toward butyrate producers

Contraindications

Pregnancy and lactation

Known colorectal adenocarcinoma or high-grade dysplasia under surveillance

Solid-organ transplant recipients on maintenance immunosuppression

Exocrine pancreatic insufficiency with faecal elastase below 100 µg/g

Acute pancreatitis within the first 72 hours of symptom onset, outside a supervised trial

Advanced cirrhosis (Child-Pugh Class C) or chronic kidney disease with eGFR below 30 mL/min/1.73 m²

Children and adolescents under 18

Key Interactions

Lipase-inhibiting medication (orlistat)

Pancreatic enzyme replacement (pancrelipase, as Creon or Zenpep)

Other histone deacetylase inhibitors (valproate, vorinostat, romidepsin)

Immunosuppressants (tacrolimus, mycophenolate, prednisone)

Antacids and proton pump inhibitors (omeprazole, esomeprazole)

Butyrate salts (sodium butyrate, calcium-magnesium butyrate)

Nicotinic acid and ketone salts (beta-hydroxybutyrate)

Fibre, resistant starch and prebiotics (inulin, partially hydrolysed guar gum)

Other interventions (faecal microbiota transplantation, probiotics)

Risk & Side Effects

Medium: Gastrointestinal intolerance; odour, taste and belching

Low: Myalgia and central nervous system effects; raised blood nitrogen waste

Speculative: Support of established colonic abnormal growth (conflicted); sustained non-selective histone deacetylase inhibition; immune dampening; unpredictable delivery when fat digestion is altered

Monitoring

Marker	Target	Why
High-sensitivity C-reactive protein	< 1.0 mg/L	General inflammation; fell in butyrate trials
Faecal calprotectin	< 50 µg/g	Colonic inflammation; the marker that moved most in butyrate trials
Stool short-chain fatty acid panel	No established target; track change from the individual's own baseline	Shows whether colonic butyrate is low enough to leave headroom
Blood urea nitrogen and creatinine	Urea 10–16 mg/dL; creatinine 0.8–1.1 mg/dL	The only laboratory abnormality attributed to tributyrin in dose-escalation work
Alanine aminotransferase	< 25 U/L (men), < 20 U/L (women)	Liver effects are the best-supported preclinical signal, favourable in animals but unverified in people
Fasting insulin and HOMA-IR	Insulin < 8 µIU/mL; HOMA-IR < 1.5	Insulin resistance improved in the butyrate obesity trial
Haemoglobin A1c	5.0–5.4%	Slower-moving confirmation of any glycaemic change

Cadence: Baseline before starting; symptom and stool assessment at 4 weeks; metabolic panel and inflammation markers at 12 weeks; then every 6–12 months if use continues

Qualitative Assessment

Stool form and frequency, recorded on a consistent scale rather than from memory
Bloating, gas and abdominal discomfort, scored daily for the first two weeks
Belching and rancid aftertaste, the earliest and commonest reason use stops
Energy through the afternoon, and tolerance of previously troublesome meals
Sleep quality and time to fall asleep, given the circadian signal in the butyrate trial
Cognitive clarity and word-finding, the domains that moved in the Parkinson's disease study

Tributyrin for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment